| Previous close | 13.20 |
| Open | 13.20 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 77.50 |
| Expiry date | 2024-01-19 |
| Day's range | 13.20 - 13.20 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- GlobeNewswire
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal squamous cell carcinoma1 Statistically significant survival benefit with tislelizumab plus chemotherapy was observed regardless of PD-L1 status and consistent across all patient subgroups1 Novartis to discuss results of multi-regional RATIONALE 306 study, the seventh positive Phase III trial readout for t
- Zacks
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
- Zacks
Q2 Earnings Season Preview and Featured Analyst Reports for J&J, AMD & Union Pacific
Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).
